Reports 2023 revenue $4.8M vs. $6M last year. “Over the course of 2023, we continued to build the foundation for future growth, spearheaded by the $140 million royalty-backed financing of VABYSMO in the fourth quarter,” stated Owen Hughes, Chief Executive Officer of XOMA. “We entered 2024 with the strongest cash position in the Company’s history, several key upcoming clinical and regulatory events, including the potential approvals of Day One’s tovorafenib and Zevra Therapeutics’ arimoclomol NDAs, and a growing pipeline of asset opportunities.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XOMA:
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- Is XOMA a Buy, Before Earnings?
- XOMA to Present at Upcoming Investor Conferences in March
- Kinnate Biopharma price target raised to $2.59 from $1.50 at Stifel
- Xoma acquisition boosts royalty growth potential, says H.C. Wainwright
